摘要
背景与目的目前放射治疗、化疗综合治疗Ⅲ期非小细胞肺癌的方法已被广泛采用,但关于NSCLC三维适形放射治疗(3D-CRT)同步化疗的报道还较少。本研究旨在通过3D-CRT同步化疗与单纯3D-CRT治疗Ⅲ期NSCLC,观察3D-CRT同步化疗治疗NSCLC的疗效和毒副作用。方法88例Ⅲ期患者随机分入同步组和单放组。同步组第1周和第4周及三维适形放射治疗结束后行方案化疗(DDP:30mg,d1-3,VP-16:100mg,d1-5),共6周期。单放组行单纯常规3D-CRT治疗。结果同步组和单放组总有效率分别为90.9%和68.2%,差异有统计学意义(P<0.05);同步组患者1、2、3年生存率分别为68.8%、35.1%、19.7%,中位生存期为18.8个月;单放组患者1、2、3年生存率分别为38.9%、22.8%、12.4%,中位生存期为12.6个月,两组比较差异有统计学意义(P<0.05)。两组不良反应除骨髓抑制外,差异无统计学意义。结论三维适形放射治疗结合同步化疗治疗Ⅲ期NSCLC近期疗效较好,生存率提高,毒性也有所增加,但能为绝大多数患者耐受。
Background and objective The outcome of treatment for stage Ⅲ non-small cell lung cancer （NSCLC） by radiotherapy plus concurrent chemotherapy is poor. This study was aimed to investigate the feasibility of three-dimensional conformal radiotherapy （3D-CRT） plus concurrent cisplatin-based chemotherapy on the patients with stage Ⅲ non-small cell lung cancer. Methods 88 cases with stage Ⅲ NSCLC from August 2004 to June 2007 were divided randomly into concurrent group and 3D-CRT alone group. Results The overall response rate （CR＋PR） in concurrent group and 3D-CRT alone group were 90.9% and 68.2% respectively （P〈0.05）. The 1, 2, 3-year overall survival rate in concurrent group and 3D-CRT alone group were 68.8%, 3S.1%, 19.7% and 38.9%, 22.8%, 12.4% respectively. The median survival was 18.8 months, and 12.6 months, respectively, and the difference of the toxicity （except leukocytopenia） was not statistically significant in two groups （P〉0.05）. Conclusion 3D-CRT combined with concurrent chemotherapy has better response and shorter treatment course than the 3D- CRT alone, and increases the overall survival, so it is the best method for the treatment stage Ⅲ NSCLC.
出处
《中国肺癌杂志》
CAS
2009年第9期1009-1012,共4页
Chinese Journal of Lung Cancer
关键词
肺肿瘤
三维适形放射治疗
同步化疗
生存率
毒副反应
Lung neoplasmas
Three-dimensional conformal radiotherapy
Concurrent chemotherapy
Survival
Toxicity
